Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.

NPJ Parkinsons Dis · 2022 · PMC8861053 · PMID 35190544

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

In early PD patients, the improvement observed with safinamide at 200 mg daily failed to reach statistical significance, probably in relation to the higher discontinuations rate registered in the group treated at this dosage, which may have masked the clinical benefit.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.